<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00319982</url>
  </required_header>
  <id_info>
    <org_study_id>001936</org_study_id>
    <secondary_id>K23HL078901</secondary_id>
    <nct_id>NCT00319982</nct_id>
  </id_info>
  <brief_title>Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem</brief_title>
  <official_title>Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot clinical trial to assess whether the administration of diltiazem may be able
      to decrease the development or progression of hypertrophic cardiomyopathy (HCM). Diltiazem is
      a commonly used medication for the treatment of high blood pressure and studies on animals
      with HCM suggest that diltiazem decreases disease development. This study specifically
      targets individuals in the &quot;prehypertrophic&quot; phase of HCM-- those with documented sarcomere
      gene mutations without echocardiographic or EKG evidence of LVH, and therefore without a
      clinical diagnosis of HCM.

      The hypothesis of this study is that starting diltiazem administration early in life (in the
      prehypertrophic phase) will decrease the progression of HCM in individuals with sarcomere
      gene mutations. This will be assessed by looking at an improvement in the heart's ability to
      relax using echocardiography, as well as exploratory analyses of a broad range of features
      reflecting the heart's structure and function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY RATIONALE:

      Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by histopathologic
      findings of cardiac myocyte disarray and fibrosis, and clinical manifestations of unexplained
      left ventricular hypertrophy (LVH), diastolic dysfunction, and an increased risk for sudden
      death. It is a common disorder affecting approximately 1 in 1000 individuals in the general
      population. Dominantly-acting mutations in contractile proteins—genes encoding the elements
      of the sarcomere apparatus-- have been shown to be the genetic etiology of HCM. Contemporary
      management strategies for HCM focus on identification of individuals at high risk for sudden
      death and management of symptoms. There is no current therapy available which address disease
      prevention or phenotypic attenuation.

      Dysregulation of intracellular calcium handling is a fundamental and early manifestation of
      sarcomere mutations. Animal models of HCM demonstrated abnormal Ca2+ cycling prior to the
      development of myocyte disarray or hypertrophy. Manipulation of intracellular Ca2+ handling
      in young, pre-hypertrophic mice with HCM via administration of the L-type Ca2+ channel
      blocker, diltiazem, attenuated the degree of hypertrophic remodeling and diminished the
      phenotypic manifestations of sarcomere mutations. Notably, if treatment was initiated later
      in life, after LVH was allowed to develop, there was no significant effect. Although this
      strategy has not yet been tested in humans, diltiazem is a commonly-used medication with a
      long track record of safety and tolerability.

      Mutation carriers without discernible echocardiographic left ventricular hypertrophy
      (designated G+/LVH-) represent a unique population of individuals with early disease who are
      ideal candidates for preemptive strategies to attempt to attenuate phenotypic development.
      One clinical marker of early disease is a subtle abnormality of LV diastolic function,
      detectable by tissue Doppler echocardiography (TDI). Individuals with sarcomere mutations
      have evidence of abnormal diastolic function by TDI as demonstrated by a 13-19% reduction in
      early myocardial relaxation velocities (E'), as compared to healthy controls.

      Since LVH develops in a age-dependent manner, genetic diagnosis provides a mechanism for
      early identification of individuals at risk for developing HCM, prior to the expression of
      diagnostic clinical manifestations. One goal for the next era of medicine is to evolve from
      contemporary symptom palliation of late stage disease to early preventive strategies which
      instead strive to alter the natural history of disease development.

      STUDY OBJECTIVES:

      The goal of this trial is to evaluate the safety, feasibility, and efficacy of diltiazem
      administration in attenuating the natural history of HCM, focusing on tolerability and impact
      on diastolic function. The primary efficacy endpoint will be an improvement in diastolic
      function in G+/LVH- subjects receiving active therapy as compared to placebo, as measured by
      improved mean tissue Doppler echocardiographic early diastolic velocity (E') in the diltiazem
      group compared to the placebo group 2 years after randomization. As a pilot trial, treatment
      effects on multiple related parameters including changes in LV dimensions and mass,
      development of overt LVH, development of cardiac magnetic resonance (CMR) evidence of
      fibrosis, and levels of serum biomarkers will be analyzed in an exploratory manner to more
      fully characterize potential treatment effect. The safety endpoint will be no excess of all
      cause death, cardiovascular death (including sudden death), heart failure requiring
      medication or hospitalization, or a significant difference in the development of
      symptoms/side effects which necessitate discontinuation of treatment in the active vs placebo
      arm.

      STUDY DESIGN AND SCHEMA A placebo-controlled, randomized double-blind Pilot clinical trial.

      Eligible G+/LVH- subjects will undergo baseline studies (physical examination,
      echocardiography, CMR, blood tests) and will be randomized to receive diltiazem or placebo in
      a double blind fashion. There is a 3 week titration phase to increase the dose of study drug
      to target. The total duration of the study protocol is 5 years: study drug will be continued
      for a total of 4 years and a 1 year post-treatment evaluation will be performed. The primary
      endpoint will be assessed after 2 years of treatment.

      Study visits and data collection consist of echocardiography at 3, 6, 12, 18, 24, 36,48, and
      60 months. Annual evaluations consisting of physical exam, echocardiography, EKG, and
      measurement of serum biomarkers will also be performed.

      PATIENT POPULATION Eligible subjects will have an identified sarcomere mutation with no
      clinical evidence of LVH. Children age 15 years and older will be enrolled at Brigham and
      Women's Hospital; children age 5-15 years will be enrolled via Children's Hospital Boston.

      Major Inclusion Criteria:

        -  Preclinical HCM as defined by above G+/LVH- criteria

        -  Able to provide informed consent (or parental consent)

      Major Major Exclusion Criteria:

      Contraindication to diltiazem administration, including the following pre-existing
      conditions:

        -  Second or third degree atrioventricular block

        -  Symptomatic heart failure

        -  Sick sinus syndrome

        -  Concomitant treatment with verapamil and/or beta-blockers

        -  Concomitant treatment with cyclosporine or FK506

        -  Impaired hepatic or renal function

        -  Age &lt;5 years

        -  Pregnant or breastfeeding women

      PRIMARY AND SECONDARY ENDPOINTS

      PRIMARY ENDPOINT:

      Improvement in diastolic function as reflected by the averaged E' velocity compared to
      baseline (E' velocities improve, remain stable, or decline less in the treated group) 2 years
      following initiation of treatment.

      As a pilot study, numerous other parameters reflecting myocardial structure and function will
      also be explored.

      SECONDARY ENDPOINTS:

        -  Development of left ventricular hypertrophy

        -  Improvement in, stability of, or attenuation of increase in serum biomarkers (e.g., BNP,
           ST2, PICP, PIIINP, PINP) at 3, 6, and 18 months, annually and at study end

        -  Improvement in, stability of or attenuation of increase in CMR evidence of myocardial
           fibrosis

           - Impact on left ventricular morphology, remodeling, and cavity size

        -  Safety: no excess of all cause death, CV death (including sudden death), heart failure
           requiring medication or hospitalization; No excess of adverse events

        -  Tolerability: no excess need to reduce or withdraw study medication; no significant
           difference in adherence to study medication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity</measure>
    <time_frame>Baseline and final study visits</time_frame>
    <description>The change in E' velocity (difference between final value - baseline value) was compared between participants who received diltiazem and those who received placebo to gauge treatment response. Please note that the total duration on treatment varied between study subjects to maximize time on treatment for the trial. Specifically, subjects that enrolled earliest had the longest duration of treatment; those who enrolled latest had the shortest duration of treatment with a minimum treatment duration of 1 year. All analyses examine the final study visit on treatment to the baseline visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Diltiazem Treatment</measure>
    <time_frame>Baseline through final study visits</time_frame>
    <description>Adverse events were compared between participants assigned to diltiazem and those assigned to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Diltiazem on Heart Rate</measure>
    <time_frame>Baseline and final study visits</time_frame>
    <description>Change in Value (Difference between Final and Baseline Visits)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Cavity Size</measure>
    <time_frame>Baseline and final study visits</time_frame>
    <description>Change in Left Ventricular End-Diastolic Diameter z-score (Final Value - Baseline Value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of Left Ventricular Hypertrophy</measure>
    <time_frame>Baseline through final study visits</time_frame>
    <description>The number of participants who developed overt left ventricular hypertrophy during the duration of the trial was analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Study Medication</measure>
    <time_frame>Duration of the trial</time_frame>
    <description>Adherence to study medication was assessed by pill count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Diltiazem on Systolic Blood Pressure</measure>
    <time_frame>Baseline and final study visits</time_frame>
    <description>Change in Value (Difference between Final and Baseline Visits)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>I- Diltiazem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diltiazem- study medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period</description>
    <arm_group_label>I- Diltiazem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator (double-blind allocation of study medication)</description>
    <arm_group_label>II- Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preclinical HCM (identified sarcomere mutation with no clinical evidence of left
             ventricular hypertrophy)

          -  Able to provide informed consent (or parental consent)

        Exclusion Criteria:

          -  Contraindication to diltiazem administration

          -  Impaired hepatic or renal function

          -  Age &lt; 5 years

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Y Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ, Giewat M, Seidman CE, Seidman JG. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest. 2000 Dec;106(11):1351-9.</citation>
    <PMID>11104788</PMID>
  </reference>
  <reference>
    <citation>Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, Reiken S, Mende U, Marks AR, Kass DA, Seidman CE, Seidman JG. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002 Apr;109(8):1013-20.</citation>
    <PMID>11956238</PMID>
  </reference>
  <reference>
    <citation>Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002 Jun 25;105(25):2992-7.</citation>
    <PMID>12081993</PMID>
  </reference>
  <reference>
    <citation>Ho CY, Seidman CE. A contemporary approach to hypertrophic cardiomyopathy. Circulation. 2006 Jun 20;113(24):e858-62. Review.</citation>
    <PMID>16785342</PMID>
  </reference>
  <reference>
    <citation>Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, Sparks E, Abbasi SA, Kwong RY, Antman EM, Semsarian C, González A, López B, Diez J, Orav EJ, Colan SD, Seidman CE. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. JACC Heart Fail. 2015 Feb;3(2):180-8. doi: 10.1016/j.jchf.2014.08.003. Epub 2014 Oct 31.</citation>
    <PMID>25543971</PMID>
  </reference>
  <reference>
    <citation>Ho CY, López B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P, Kwong R, González A, Colan SD, Seidman JG, Díez J, Seidman CE. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010 Aug 5;363(6):552-63. doi: 10.1056/NEJMoa1002659.</citation>
    <PMID>20818890</PMID>
  </reference>
  <reference>
    <citation>Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, Cirino AL, Lakdawala NK, Orav EJ, González A, López B, Díez J, Jerosch-Herold M, Kwong RY. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013 May 1;6(3):415-22. doi: 10.1161/CIRCIMAGING.112.000333. Epub 2013 Apr 2.</citation>
    <PMID>23549607</PMID>
  </reference>
  <reference>
    <citation>Valente AM, Lakdawala NK, Powell AJ, Evans SP, Cirino AL, Orav EJ, MacRae CA, Colan SD, Ho CY. Comparison of echocardiographic and cardiac magnetic resonance imaging in hypertrophic cardiomyopathy sarcomere mutation carriers without left ventricular hypertrophy. Circ Cardiovasc Genet. 2013 Jun;6(3):230-7. doi: 10.1161/CIRCGENETICS.113.000037. Epub 2013 May 20.</citation>
    <PMID>23690394</PMID>
  </reference>
  <reference>
    <citation>Lakdawala NK, Thune JJ, Maron BJ, Cirino AL, Havndrup O, Bundgaard H, Christiansen M, Carlsen CM, Dorval JF, Kwong RY, Colan SD, Køber LV, Ho CY. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy. Am J Cardiol. 2011 Dec 1;108(11):1606-13. doi: 10.1016/j.amjcard.2011.07.019. Epub 2011 Sep 21.</citation>
    <PMID>21943931</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2006</study_first_submitted>
  <study_first_submitted_qc>April 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2006</study_first_posted>
  <results_first_submitted>January 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2015</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Carolyn Yung Ho, MD</investigator_full_name>
    <investigator_title>Associate Physician</investigator_title>
  </responsible_party>
  <keyword>Hypertrophic Cardiomyopathy</keyword>
  <keyword>Left ventricular hypertrophy</keyword>
  <keyword>Diltiazem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the HCM clinics at Brigham and Women’s Hospital (Boston, MA), Boston Children’s Hospital (Boston, MA), and Royal Prince Alfred Hospital (Sydney, Australia). Participants were recruited from 2006 through 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>I- Diltiazem (Active Arm)</title>
          <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
        </group>
        <group group_id="P2">
          <title>II- Placebo</title>
          <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants enrolled through Brigham and Women’s Hospital (Boston, MA), Boston Children’s Hospital, and Royal Prince Alfred Hospital (Sydney, Australia) were randomized 1:1 to diltiazem or placebo. Participants were 5-39 years old, carried the sarcomere mutation presumed to cause HCM in the family, and had normal LV wall thickness by echo.</population>
      <group_list>
        <group group_id="B1">
          <title>I- Diltiazem</title>
          <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
        </group>
        <group group_id="B2">
          <title>II- Placebo</title>
          <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.7"/>
                    <measurement group_id="B2" value="17.3" spread="2.1"/>
                    <measurement group_id="B3" value="15.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity</title>
        <description>The change in E' velocity (difference between final value - baseline value) was compared between participants who received diltiazem and those who received placebo to gauge treatment response. Please note that the total duration on treatment varied between study subjects to maximize time on treatment for the trial. Specifically, subjects that enrolled earliest had the longest duration of treatment; those who enrolled latest had the shortest duration of treatment with a minimum treatment duration of 1 year. All analyses examine the final study visit on treatment to the baseline visit.</description>
        <time_frame>Baseline and final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity</title>
          <description>The change in E' velocity (difference between final value - baseline value) was compared between participants who received diltiazem and those who received placebo to gauge treatment response. Please note that the total duration on treatment varied between study subjects to maximize time on treatment for the trial. Specifically, subjects that enrolled earliest had the longest duration of treatment; those who enrolled latest had the shortest duration of treatment with a minimum treatment duration of 1 year. All analyses examine the final study visit on treatment to the baseline visit.</description>
          <units>cm/sec (difference final-baseline)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.27"/>
                    <measurement group_id="O2" value="-0.21" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in E' Velocity comparing baseline and final study visits</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <p_value_desc>Adjusted for age, sex, genotype, family relations, and baseline value. p&lt;0.05 considered statistically significant.</p_value_desc>
            <method>Generalized estimating equation</method>
            <method_desc>Generalized estimating equation approach accounting for an exchangeable correlation structure within families</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Diltiazem Treatment</title>
        <description>Adverse events were compared between participants assigned to diltiazem and those assigned to placebo</description>
        <time_frame>Baseline through final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Diltiazem Treatment</title>
          <description>Adverse events were compared between participants assigned to diltiazem and those assigned to placebo</description>
          <units>Participants Reporting Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adverse Events</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Diltiazem on Heart Rate</title>
        <description>Change in Value (Difference between Final and Baseline Visits)</description>
        <time_frame>Baseline and final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Diltiazem on Heart Rate</title>
          <description>Change in Value (Difference between Final and Baseline Visits)</description>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="2.2"/>
                    <measurement group_id="O2" value="2.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.06</p_value>
            <p_value_desc>Adjusted for age, sex, genotype, family relations, and baseline value. p&lt;0.05 considered statistically significant.</p_value_desc>
            <method>Generalized Estimating Equation</method>
            <method_desc>Generalized estimating equation approach accounting for an exchangeable correlation structure within families</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Cavity Size</title>
        <description>Change in Left Ventricular End-Diastolic Diameter z-score (Final Value - Baseline Value)</description>
        <time_frame>Baseline and final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Cavity Size</title>
          <description>Change in Left Ventricular End-Diastolic Diameter z-score (Final Value - Baseline Value)</description>
          <units>z-score units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.17"/>
                    <measurement group_id="O2" value="-0.53" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in LV End-Diastolic Diameter z-score from baseline to final visit</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted for age, sex, genotype, family relations, and baseline value</p_value_desc>
            <method>Generalized Estimating Equation</method>
            <method_desc>Generalized estimating equation approach accounting for an exchangeable correlation structure within families</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Development of Left Ventricular Hypertrophy</title>
        <description>The number of participants who developed overt left ventricular hypertrophy during the duration of the trial was analyzed</description>
        <time_frame>Baseline through final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Development of Left Ventricular Hypertrophy</title>
          <description>The number of participants who developed overt left ventricular hypertrophy during the duration of the trial was analyzed</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Study Medication</title>
        <description>Adherence to study medication was assessed by pill count</description>
        <time_frame>Duration of the trial</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Study Medication</title>
          <description>Adherence to study medication was assessed by pill count</description>
          <units>percentage of pills taken</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" spread="10.8"/>
                    <measurement group_id="O2" value="90" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage adherent to study medication</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Diltiazem on Systolic Blood Pressure</title>
        <description>Change in Value (Difference between Final and Baseline Visits)</description>
        <time_frame>Baseline and final study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>I- Diltiazem</title>
            <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
          </group>
          <group group_id="O2">
            <title>II- Placebo</title>
            <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Diltiazem on Systolic Blood Pressure</title>
          <description>Change in Value (Difference between Final and Baseline Visits)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.7"/>
                    <measurement group_id="O2" value="2.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>Adjusted for age, sex, genotype, family relations, and baseline value</p_value_desc>
            <method>Generalized estimating equation</method>
            <method_desc>Generalized estimating equation approach accounting for an exchangeable correlation structure within families</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of Trial</time_frame>
      <group_list>
        <group group_id="E1">
          <title>I- Diltiazem</title>
          <description>Diltiazem: Titrated to a target dose of 360 mg daily (sustained release formulation) for the duration of the study period</description>
        </group>
        <group group_id="E2">
          <title>II- Placebo</title>
          <description>Placebo Comparator
Placebo: Placebo comparator (double-blind allocation of study medication)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lightheadeness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/GI distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of participants and short follow-up duration. Currently available tools to monitor treatment response/ phenotypic progression are may lack adequate resolution. The penetrance of sarcomere mutations is variable and may not be complete.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carolyn Ho, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-5685</phone>
      <email>cho@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

